Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction-dose peginterferon alfa-2a plus ribavirin with epoetin beta support in HIV/HCV coinfected adults
2004-000907-16Phase 4Active
- Sponsor
- IrsiCaixa
- Start
- Nov 2005
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a, ribavirin and epoetin beta in hepatitis C virus infection (2 arms), sponsored by IrsiCaixa. Primary endpoint: Percentage of patients with undetectable HCV RNA at 12 weeks. Started Nov 2005; status: active.
02
Drugs
peginterferon alfa-2aribavirinepoetin beta
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2004-000907-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000907-16.